Eledon Pharmaceuticals (ELDN) News Today $5.30 +0.65 (+13.98%) (As of 11/1/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Promising Clinical Trials and Strong Financial Position Make Eledon Pharmaceuticals a Compelling InvestmentOctober 30 at 2:55 PM | markets.businessinsider.comNoble Financial Reaffirms Their Buy Rating on Eledon Pharmaceuticals (ELDN)October 30 at 2:55 PM | markets.businessinsider.comBuy Rating Justified for Eledon Pharmaceuticals Amid Promising Clinical Developments and Financial StabilityOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals prices 18.36M shares at $3.65 in underwritten offeringOctober 29, 2024 | markets.businessinsider.comEledon Pharmaceuticals Shares Hit 52-Week High After Positive Trial DataOctober 29, 2024 | marketwatch.comEledon: Changing Scope Of Immunosuppressive Drug Space With TegoprubartOctober 29, 2024 | seekingalpha.comEledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsOctober 29, 2024 | globenewswire.comEledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago MedicineOctober 29, 2024 | globenewswire.comEledon Pharma (NASDAQ:ELDN) Stock Quotes, Forecast and News SummaryOctober 2, 2024 | benzinga.comNantahala Capital Management LLC Invests $1.58 Million in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Nantahala Capital Management LLC purchased a new stake in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 600,000 shares of the company's stoOctober 1, 2024 | marketbeat.comEledon Pharmaceuticals’ Tegoprubart: A Strong Buy Based on Industry-Wide Validation and Promising Drug DataSeptember 24, 2024 | markets.businessinsider.comEledon Pharmaceuticals to Present at the Cantor Global Healthcare ConferenceSeptember 11, 2024 | globenewswire.comAnalysts Are Bullish on These Healthcare Stocks: Eledon Pharmaceuticals (ELDN), Opthea Limited Sponsored ADR (OPT)September 9, 2024 | markets.businessinsider.comEledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant PatientsSeptember 4, 2024 | globenewswire.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Earn Q3 2024 Earnings of ($0.20) Per ShareEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2024 earnings estimates for Eledon Pharmaceuticals in a research report issued on Tuesday, August 20th. Leerink Partnrs analyst T. Smith now expects that the company will earn ($0.2August 23, 2024 | marketbeat.comBuy Rating Justified by Eledon Pharmaceuticals’ Strategic Progress and Growth PotentialAugust 22, 2024 | markets.businessinsider.comVanguard Group Inc. Buys 273,703 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Vanguard Group Inc. raised its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 39.4% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 969,121 shares of the company's stock afteAugust 20, 2024 | marketbeat.com2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360%August 19, 2024 | msn.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 16.1% in JulyEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totalling 108,100 shares, a decline of 16.1% from the July 15th total of 128,800 shares. Based on an average daily volume of 158,400 shares, the short-interest ratio is presently 0.7 days.August 16, 2024 | marketbeat.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating ResultsAugust 15, 2024 | finanznachrichten.deEledon Expects to Restate Results, Delays Quarterly ReportAugust 14, 2024 | marketwatch.comEledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating ResultsAugust 14, 2024 | globenewswire.comEledon Pharmaceuticals Inc (ELDN)August 10, 2024 | investing.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 1.7% Eledon Pharmaceuticals (NASDAQ:ELDN) Trading Down 1.7%August 2, 2024 | marketbeat.comEledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ RejectionJuly 29, 2024 | globenewswire.com2 Penny Stocks Wall Street Expects to Soar Over 400%July 22, 2024 | msn.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Significant Growth in Short InterestEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 170,600 shares, a growth of 225.6% from the June 15th total of 52,400 shares. Based on an average daily trading volume, of 203,700 shares, the days-to-cover ratio is currently 0.8 days.July 11, 2024 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Up 7.4% in JuneEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) was the target of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 52,400 shares, a growth of 7.4% from the May 31st total of 48,800 shares. Based on an average daily trading volume, of 210,300 shares, the days-to-cover ratio is currently 0.2 days.July 2, 2024 | marketbeat.comEledon to Participate in the Leerink Partners Therapeutics Forum: I&I and MetabolismJuly 2, 2024 | globenewswire.comPenny Stock Picks: 3 Companies Poised to Graduate to the Big LeaguesJune 17, 2024 | investorplace.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Short Interest Down 74.5% in MayEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Get Free Report) saw a large decrease in short interest during the month of May. As of May 31st, there was short interest totalling 48,800 shares, a decrease of 74.5% from the May 15th total of 191,500 shares. Based on an average daily volume of 200,600 shares, the short-interest ratio is presently 0.2 days.June 12, 2024 | marketbeat.com3 High-Potential Penny Stocks to Turn $1000 into $1 Million: June 2024June 11, 2024 | investorplace.comArmistice Capital LLC Purchases 365,000 Shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN)Armistice Capital LLC lifted its stake in shares of Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) by 20.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,189,000 shares of the company's stock after aJune 6, 2024 | marketbeat.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Expected to Post Q2 2024 Earnings of ($0.36) Per ShareEledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - Research analysts at Lifesci Capital issued their Q2 2024 EPS estimates for shares of Eledon Pharmaceuticals in a report issued on Tuesday, June 4th. Lifesci Capital analyst R. Katkhuda expects that the company will post earnings per sharJune 5, 2024 | marketbeat.comEledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationJune 3, 2024 | globenewswire.comEledon Pharmaceuticals’ Tegoprubart Shows Promising Trial Results and Fuels Buy RatingMay 10, 2024 | markets.businessinsider.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | finanznachrichten.deEledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial ResultsMay 9, 2024 | globenewswire.comEledon Pharmaceuticals to Present Updated Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Transplant CongressMay 9, 2024 | globenewswire.comBrokers Issue Forecasts for Eledon Pharmaceuticals, Inc.'s Q2 2024 Earnings (NASDAQ:ELDN)Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN - Free Report) - HC Wainwright issued their Q2 2024 EPS estimates for Eledon Pharmaceuticals in a research note issued on Tuesday, May 7th. HC Wainwright analyst V. Bernardino forecasts that the company will post earnings per share of ($0.32) for the quarMay 9, 2024 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Agenus (AGEN)May 8, 2024 | markets.businessinsider.comEledon Pharmaceuticals, Inc.: Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionMay 7, 2024 | finanznachrichten.deEledon Pharmaceuticals’ Tegoprubart Shows Promising Clinical Advancements, Reinforcing Buy Rating and Elevated Price TargetMay 7, 2024 | markets.businessinsider.comNano-Cap Eledon Pharmaceuticals' Investigational Drug Shows Safety In Early Organ Transplant Study, Analyst Boosts Forecast On Increased ConfidenceMay 7, 2024 | msn.comEledon Pharmaceuticals (NASDAQ:ELDN) Price Target Increased to $16.00 by Analysts at HC WainwrightHC Wainwright boosted their target price on shares of Eledon Pharmaceuticals from $13.00 to $16.00 and gave the company a "buy" rating in a research report on Tuesday.May 7, 2024 | marketbeat.comEledon Pharmaceuticals Announces Oversubscribed $50 Million Private PlacementMay 7, 2024 | finance.yahoo.comEledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant RejectionMay 7, 2024 | globenewswire.com2 Penny Stocks That Wall Street Predicts Will Soar Over 300%April 29, 2024 | msn.comEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 29, 2024 | finanznachrichten.deELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023March 29, 2024 | msn.com Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Why Buffett, Bezos, & Congress Are Piling Into This One Sector (Ad)Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market… Click here for the details ELDN Media Mentions By Week ELDN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELDN News Sentiment▼0.590.43▲Average Medical News Sentiment ELDN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELDN Articles This Week▼81▲ELDN Articles Average Week Get Eledon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CRVS News Today LRMR News Today ARCT News Today VERV News Today AQST News Today KALV News Today SIGA News Today SAGE News Today VALN News Today PRTC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELDN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ELDN Stock Alerts